drugset / Trial / NCT00855699

Alcohol Detoxification in Primary Care Treatment (ADEPT)

NCT00855699

Phase 4 Completed 36 enrolled University of Bristol
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Once someone becomes dependent on alcohol (alcoholic), the risks of complications from alcohol withdrawal when they stop drinking grow. These can include a life-threatening fit or delirium tremens (see things, become frightened). To prevent such complications, people take medication such as benzodiazepines (e.g., valium or librium) in reducing doses for about a week; this is called detoxification or 'detox.' In the UK effective alcohol treatment exists but little is known about what is the best detox medication. Alternative drugs to benzodiazepines appear to protect the brain from the toxicity of alcohol withdrawal and to reduce the likelihood of drinking again. This study will examine the feasibility of comparing medication regimens for alcohol detox for the first time in primary care. It will include a standard detox regimen (librium over 8 days) alone and together with a drug, acamprosate, that has been shown to reduce toxicity of alcohol withdrawal in preclinical models and is used after detox to help people remain sober. It will focus on the practicalities of doing such a study as well as assessing how people feel (withdrawal symptoms) and do (drinking during first month).

Timeline

Start
2009-11
Primary completion
2010-07
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Acamprosate Small molecule 666 mg

Indications